BioSpace News Archive

EpicentRx announced it will be participating in two upcoming conferences where presentations on RRx-001, its late-stage first-in-class NLRP3 inhibitor, will focus on the compound’s potential to protect against inflammasome-driven diseases such as Parkinson’s disease and other chronic diseases.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and Vickers Vantage Corp.

Cumulus Neuroscience, a global digital health company developing multi-domain digital biomarkers for the brain, was selected by renowned life sciences forum CNS Summit to present at its annual Innovation Showcase, and for a poster presentation illustrating the reliability of real world digital end-points of functional neurophysiology.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that shares of its common stock will trade on the Nasdaq Capital Market on Friday, November 11, 2022 under the ticker symbol “SCLX”.

BioGX announced that the US FDA has updated their original Direct Sample Xfree™ COVID-19 Emergency Use Authorization to increase the shelf-life of the assay reagent to 15 months and expand its use to additional real-time PCR platforms, including BioGX’s pixl™ real-time PCR platform.

GT Biopharma, Inc. will present two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting, to be held in Boston, Massachusetts and virtually on November 8-12, 2022.

Athersys, Inc. announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional investors for the purchase of 5,004,545 shares of the Company’s common stock and warrants to purchase up to 10,009,090 of common stock at a combined purchase price of $1.10, resulting in gross proceeds of approximately $5.5 million before deducting placement agent fees and other offering expenses.

Inventiva reported its cash position as of September 30, 2022 and its revenues for the first nine months of 2022.

Lyell Immunopharma, Inc. announced that members of its senior management team will participate in the Barclays Virtual Fireside Chat Series on Thursday, November 17, at 11 a.m., ET.

Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the quarter ended September 30, 2022, and recent corporate updates.